A detailed history of Stifel Financial Corp transactions in Spring Works Therapeutics, Inc. stock. As of the latest transaction made, Stifel Financial Corp holds 27,193 shares of SWTX stock, worth $887,579. This represents 0.0% of its overall portfolio holdings.

Number of Shares
27,193
Previous 20,457 32.93%
Holding current value
$887,579
Previous $1.01 Million 1.79%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$36.06 - $47.62 $242,900 - $320,768
6,736 Added 32.93%
27,193 $1.02 Million
Q1 2024

May 13, 2024

BUY
$36.5 - $52.5 $82,161 - $118,177
2,251 Added 12.36%
20,457 $1.01 Million
Q4 2023

Feb 12, 2024

SELL
$18.94 - $37.24 $60,077 - $118,125
-3,172 Reduced 14.84%
18,206 $664,000
Q3 2023

Nov 13, 2023

BUY
$23.12 - $31.38 $6,103 - $8,284
264 Added 1.25%
21,378 $494,000
Q2 2023

Aug 14, 2023

BUY
$23.15 - $32.71 $132,834 - $187,689
5,738 Added 37.32%
21,114 $553,000
Q1 2023

May 12, 2023

BUY
$24.97 - $34.05 $16,005 - $21,826
641 Added 4.35%
15,376 $395,000
Q4 2022

Feb 13, 2023

SELL
$21.73 - $28.72 $27,857 - $36,819
-1,282 Reduced 8.0%
14,735 $383,000
Q3 2022

Nov 14, 2022

SELL
$24.1 - $39.66 $4,265 - $7,019
-177 Reduced 1.09%
16,017 $457,000
Q2 2022

Aug 15, 2022

BUY
$18.36 - $60.07 $54,676 - $178,888
2,978 Added 22.53%
16,194 $399,000
Q1 2022

May 13, 2022

SELL
$48.97 - $65.46 $3,036 - $4,058
-62 Reduced 0.47%
13,216 $746,000
Q4 2021

Feb 14, 2022

BUY
$53.3 - $75.84 $231,481 - $329,373
4,343 Added 48.61%
13,278 $823,000
Q3 2021

Nov 15, 2021

BUY
$62.66 - $88.26 $388,178 - $546,770
6,195 Added 226.09%
8,935 $566,000
Q1 2021

May 14, 2021

SELL
$65.1 - $93.59 $610,247 - $877,312
-9,374 Reduced 77.38%
2,740 $202,000
Q4 2020

Feb 12, 2021

BUY
$48.36 - $77.92 $585,833 - $943,922
12,114 New
12,114 $878,000

Others Institutions Holding SWTX

About SpringWorks Therapeutics, Inc.


  • Ticker SWTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,401,100
  • Market Cap $2.04B
  • Description
  • SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...
More about SWTX
Track This Portfolio

Track Stifel Financial Corp Portfolio

Follow Stifel Financial Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stifel Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Stifel Financial Corp with notifications on news.